Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Date:12/12/2007

ing pipeline of products, which will be validated in the clinic using the proceeds of this financing round," said Sander Slootweg, managing partner at Forbion Capital Partners. "We are delighted to invest in Fovea Pharmaceuticals and join an experienced and proven management team along with a very strong and committed group of investors."

In connection with the financing, Sander Slootweg will join the Board of Directors which is comprised of Antoine Papiernik (Sofinnova Partners), Tim Haines (Abingworth), Anthony Wild (Bows Pharmaceuticals) and Bernard Gilly. Bernard Gilly has been elected as Chairman of the Board.

"Fovea's unique product platform has led to the generation of a robust pipeline of promising therapeutic candidates for the treatment of front and back of the eye disorders. Clinical candidates are already in development and at least three new products are expected to progress into the clinic in 2008," commented Pr. Jose-Alain Sahel, Founder of Fovea Pharmaceuticals and Chairman of the Scientific Advisory Board. "It has been a pleasure to work with the talented and productive team at Fovea, and we all look forward to continued progress in exploiting the potential of these novel dedicated therapies."

In parallel to these clinical developments, a strong discovery platform has been implemented, leading to the identification of novel targets. Fovea Pharmaceuticals has recently signed a Research Partnership Agreement with Genzyme to develop gene related therapies on the basis of one of these programs, using Fovea's selected targets to treat major retinal dystrophies.

About FOVEA Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Created in May 2005, Fovea has a highly experienced board and management team. Fovea has been funded by six leading E
'/>"/>

SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... ... The global aptamers market is expected to reach $244.93 ... 17.89% between 2015 and 2020. The aptamer type segments included in this report ... is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications will ...
(Date:7/7/2015)... DE (PRWEB) , ... July 07, 2015 , ... ... that work together to lower barriers to innovation in life science R&D, has ... in the last quarter include another top ten pharmaceutical company joining as a ...
(Date:7/6/2015)... , July 6, 2015  Approximately 1% of the ... into their chromosomes. These individuals are three times more ... published in one of the nation,s leading medical journals ... in Canada.  Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... 6 (HHV-6) causes roseola (also known as "sixth disease") ...
(Date:7/6/2015)... 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused ... Viveve,s Chief Executive Officer, and Scott Durbin , Viveve,s ... 9, 2015. , , , DATE:    , ... , TIME:     , , , 12:15 PM EDT ... http://tinyurl.com/viveve   ,    ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5Pistoia Alliance Continues to Attract New Members 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3
... But when information is transmitted down fiber optic cables, ... be decoded at the other end. Two factors are ... otherwise known as the wavelength, and the orientation of ... EPFL and the Swiss Federal Laboratories for Materials Science ...
... Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh ... the 2011 Society of Surgical Oncology (SSO) conference in San ... at UPMC Shady Side Hospital as well as the Head ... of the Division of Cardiothoracic Surgery at UPMC St. Margaret ...
... Texas, April 12, 2011 Wound Management Technologies, Inc., ... care solutions, today announced that the Company has signed ... Texas to distribute CellerateRX® gel products in select states ... agreement calls for 1st year sales of at least ...
Cached Biology Technology:Better lasers for optical communications 2Precision Therapeutics' ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer 2WNDM Signs $1.5 M Multiyear Regional Distribution Agreement 2WNDM Signs $1.5 M Multiyear Regional Distribution Agreement 3
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
(Date:6/9/2015)... 09, 2015 Research and Markets  ( ... "Gesture Recognition & Touchless Sensing Market by ... & Others), Product (Biometric & Sanitary Equipment) & ... report to their offering. The total ... to reach $ 23.55 Billion by 2020 at ...
(Date:6/8/2015)... 8, 2015  The Secure Identity & ... of Troy Potter of L-3 National ... is a non-profit association that was established in ... and implementation of solutions that protect and secure ... Photo ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... Spain, show for the first time that bacteria, in ... of the sparkling wine known as Cava. They report ... the American Society for Microbiology. , "Bacteria found in ... wine quality in terms of aroma, flavor, bubble size ...
... new protein that plays a critical role in enabling the ... stress, as well as in the progressive loss of heart ... findings, they said, suggest new approaches to prevent or reverse ... the U.S. The team reports its findings in the August ...
... leishmaniasis, which is the most severe form of that group ... year. It is caused by a protozoan, Leishmania infantum, transmitted ... disease, which can rapidly lead to death if no treatment ... population is hit heavily by infection. It acts as parasite ...
Cached Biology News:After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: